Incidence of acute rejection and patient survival in combined heart–liver transplantation

Kai Zhao, Roy Wang, Malek Kamoun, Lauren Callans, Remy Bremner, Eduardo Rame, Rhondalyn McLean, Marisa Cevasco, Kim M. Olthoff, Matthew H. Levine, Abraham Shaked, Peter L. Abt – 4 March 2022 – Combined heart–liver transplantation (CHLT) is indicated for patients with concomitant end‐stage heart and liver disease or patients with amyloid heart disease where liver transplantation mitigates progression. Limited data suggest that the liver allograft provides immunoprotection for heart and kidney allografts in combined transplantation from the same donor.

Activated and nonactivated MSCs increase survival in humanized mice after acute liver injury through alcohol binging

Juan Carlos Hernandez, Da‐Wei Yeh, Joel Marh, Hye Yeon Choi, Julia Kim, Shefali Chopra, Li Ding, Matthew Thornton, Brendan Grubbs, Leonard Makowka, Linda Sher, Keigo Machida – 4 March 2022 – The ability of the liver to regenerate after injury makes it an ideal organ to study for potential therapeutic interventions. Mesenchymal stem cells (MSCs) possess self‐renewal and differentiation properties, as well as anti‐inflammatory properties that make them an ideal candidate for therapy of acute liver injury.

Associations of sarcopenia with graft failure and mortality in patients undergoing living donor liver transplantation

Ji‐Hoon Sim, Hye‐Mee Kwon, Kyung‐Won Kim, You‐Sun Ko, In‐Gu Jun, Sung‐Hoon Kim, Kyoung‐Sun Kim, Young‐Jin Moon, Jun‐Gol Song, Gyu‐Sam Hwang – 3 March 2022 – Recent studies have reported that sarcopenia influences morbidity and mortality in surgical patients. However, few studies have investigated the associations of sarcopenia with short‐term and long‐term graft failure in recipients after living donor liver transplantation (LDLT). In this study, we investigated the associations between sarcopenia and graft failure/mortality in patients undergoing LDLT.

mRNA and gene editing: Late breaking therapies in liver diseases

Nerea Zabaleta, Laura Torella, Nicholas D. Weber, Gloria Gonzalez‐Aseguinolaza – 3 March 2022 – The efficient delivery of RNA molecules to restore the expression of a missing or inadequately functioning protein in a target cell and the intentional specific modification of the host genome using engineered nucleases represent therapeutic concepts that are revolutionizing modern medicine.

Subscribe to